Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.64 |
| ▸ | TCF4 | P15884 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12154907 | 0.95 | CYP3A4 (0.64) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL748181 | 0.91 | TCF4 (0.68) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL747220 | 0.91 | CYP3A4 (0.71) | CYP3A4 | |
| SCHEMBL750160 | 0.88 | TCF4 (0.65) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL748845 | 0.88 | CYP3A4 (0.67) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL13029290 | 0.87 | TCF4 (0.60) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL13029335 | 0.87 | TCF4 (0.68) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL13070918 | 0.87 | TCF4 (0.60) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL13134838 | 0.87 | TCF4 (0.62) | CYP3A4TCF4CTNNB1 | |
| SCHEMBL12173510 | 0.87 | TCF4 (0.62) | CYP3A4TCF4CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-7932384-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-04-26 | — | — | US | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-02 | — | — | US | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Chongwae Pharma Corporation (KR) | 2010-02-04 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | CYP3A4 3595/4885TCF4 60/4885CTNNB1 9/4885 |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CYP3A4 4757/4885TCF4 50/4885CTNNB1 14/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CYP3A4 4757/4885TCF4 50/4885CTNNB1 14/4885 |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | CYP3A4 3595/4885TCF4 60/4885CTNNB1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.